Literature DB >> 21399925

The role of cardiac MR in new-onset heart failure.

Yong-Jin Kim1, Raymond J Kim.   

Abstract

In patients with heart failure, cardiovascular magnetic resonance imaging (CMR) allows a multifaceted approach to cardiac evaluation by enabling an assessment of morphology, function, perfusion, viability, tissue characterization, and blood flow during a single comprehensive examination. Given its accuracy and reproducibility, many believe CMR is the reference standard for the noninvasive assessment of ventricular volumes, mass, and function, and offers an ideal means for the serial assessment of disease progression or treatment response in individual patients. Delayed-enhancement (DE)-CMR provides a direct assessment of myopathic processes. This permits a fundamentally different approach than that traditionally taken to ascertaining the etiology of cardiomyopathy, which is vital in patients with nonischemic cardiomyopathy and incidental coronary artery disease and patients with mixed, ischemic and nonischemic cardiomyopathy. Precise tissue characterization with DE-CMR also improves the diagnosis of left ventricular thrombus, for which it is the emerging clinical reference standard. There is a growing body of literature on the utility of CMR for patient risk stratification, and its potential role in important management decisions such as for cardiac resynchronization therapy and defibrillator placement.

Entities:  

Mesh:

Year:  2011        PMID: 21399925     DOI: 10.1007/s11886-011-0179-0

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  53 in total

1.  Late gadolinium-enhanced cardiovascular magnetic resonance identifies patients with standardized definition of ischemic cardiomyopathy: a single centre experience.

Authors:  Carlos J Soriano; Francisco Ridocci; Jordi Estornell; José L Pérez-Boscá; Francisco Pomar; Alberto Trigo; Ana Planas; Mercedes Nadal; Victoria Jacas; Vicente Martinez; Rafael Paya
Journal:  Int J Cardiol       Date:  2006-07-07       Impact factor: 4.164

Review 2.  Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications.

Authors:  Han W Kim; Afshin Farzaneh-Far; Raymond J Kim
Journal:  J Am Coll Cardiol       Date:  2009-12-29       Impact factor: 24.094

3.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function.

Authors:  R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

4.  A standardized definition of ischemic cardiomyopathy for use in clinical research.

Authors:  G Michael Felker; Linda K Shaw; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

5.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

6.  Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients.

Authors:  W C Roberts; R J Siegel; B M McManus
Journal:  Am J Cardiol       Date:  1987-12-01       Impact factor: 2.778

7.  Magnetic resonance imaging and response to cardiac resynchronization therapy: relative merits of left ventricular dyssynchrony and scar tissue.

Authors:  Nina Ajmone Marsan; Jos J M Westenberg; Claudia Ypenburg; Rutger J van Bommel; Stijntje Roes; Victoria Delgado; Laurens F Tops; Rob J van der Geest; Eric Boersma; Albert de Roos; Martin J Schalij; Jeroen J Bax
Journal:  Eur Heart J       Date:  2009-07-04       Impact factor: 29.983

8.  Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction.

Authors:  Jonathan W Weinsaft; Han W Kim; Dipan J Shah; Igor Klem; Anna Lisa Crowley; Rhoda Brosnan; Olga G James; Manesh R Patel; John Heitner; Michele Parker; Eric J Velazquez; Charles Steenbergen; Robert M Judd; Raymond J Kim
Journal:  J Am Coll Cardiol       Date:  2008-07-08       Impact factor: 24.094

9.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

10.  Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis.

Authors:  Alicia M Maceira; Sanjay K Prasad; Philip N Hawkins; Michael Roughton; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2008-11-25       Impact factor: 5.364

View more
  4 in total

1.  The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure.

Authors:  Mark A Peterzan; Oliver J Rider; Lisa J Anderson
Journal:  Card Fail Rev       Date:  2016-11

Review 2.  2014 Korean guidelines for appropriate utilization of cardiovascular magnetic resonance imaging: a joint report of the Korean Society of Cardiology and the Korean Society of Radiology.

Authors:  Yeonyee E Yoon; Yoo Jin Hong; Hyung-Kwan Kim; Jeong A Kim; Jin Oh Na; Dong Hyun Yang; Young Jin Kim; Eui-Young Choi
Journal:  Korean J Radiol       Date:  2014-11-07       Impact factor: 3.500

Review 3.  2014 korean guidelines for appropriate utilization of cardiovascular magnetic resonance imaging: a joint report of the korean society of cardiology and the korean society of radiology.

Authors:  Yeonyee E Yoon; Yoo Jin Hong; Hyung-Kwan Kim; Jeong A Kim; Jin Oh Na; Dong Hyun Yang; Young Jin Kim; Eui-Young Choi
Journal:  Korean Circ J       Date:  2014-11-25       Impact factor: 3.243

Review 4.  Heart failure with mid-range or mildly reduced ejection fraction.

Authors:  Gianluigi Savarese; Davide Stolfo; Gianfranco Sinagra; Lars H Lund
Journal:  Nat Rev Cardiol       Date:  2021-09-06       Impact factor: 32.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.